Hepion Pharma Changes Accountants, No Reason Disclosed
Ticker: CTRVP · Form: 8-K · Filed: Jan 3, 2024 · CIK: 1583771
| Field | Detail |
|---|---|
| Company | Hepion Pharmaceuticals, Inc. (CTRVP) |
| Form Type | 8-K |
| Filed Date | Jan 3, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: auditor-change, administrative, 8-K
TL;DR
**HEPA is switching auditors, no big deal yet.**
AI Summary
Hepion Pharmaceuticals, Inc. (HEPA) announced on December 27, 2023, that it is changing its independent registered public accounting firm. This change is a routine administrative update, as the company has not yet disclosed the new firm or the reasons for the change. For investors, this matters because the auditor is responsible for verifying the accuracy of the company's financial statements, and any change can sometimes signal underlying issues, though in this case, no red flags are immediately apparent.
Why It Matters
A change in auditors can sometimes signal financial issues or disagreements, but without further details, this appears to be a standard administrative change for Hepion Pharmaceuticals.
Risk Assessment
Risk Level: low — The filing only reports a change in certifying accountant without providing any negative reasons or disagreements, suggesting a low immediate risk.
Analyst Insight
Investors should monitor future filings for disclosure of the new accounting firm and any details regarding the reason for the change, as this could provide more insight into the company's financial health or operational decisions.
Key Players & Entities
- Hepion Pharmaceuticals, Inc. (company) — the registrant changing its certifying accountant
- December 27, 2023 (date) — date of earliest event reported regarding the change in accountant
- Nasdaq Capital Market (company) — exchange where Hepion's Common Stock (HEPA) is registered
Forward-Looking Statements
- Hepion Pharmaceuticals will disclose the new accounting firm and the specific reasons for the change in a subsequent filing or press release. (Hepion Pharmaceuticals, Inc.) — medium confidence, target: Q1 2024
FAQ
What is the primary event reported in this 8-K filing by Hepion Pharmaceuticals, Inc.?
The primary event reported is a change in Hepion Pharmaceuticals, Inc.'s independent registered public accounting firm, as stated under 'ITEM INFORMATION: Changes in Registrant's Certifying Accountant' and 'Date of Report (Date of earliest event reported): December 27, 2023'.
What is the ticker symbol for Hepion Pharmaceuticals, Inc. and on which exchange is it traded?
Hepion Pharmaceuticals, Inc.'s ticker symbol is HEPA, and its Common Stock is registered on the Nasdaq Capital Market, as indicated under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the business address and phone number of Hepion Pharmaceuticals, Inc.?
The business address of Hepion Pharmaceuticals, Inc. is 399 Thornall Street, First Floor, Edison, NJ 08837, and its telephone number is (732) 902-4000, as listed in the 'BUSINESS ADDRESS' section.
Has Hepion Pharmaceuticals, Inc. disclosed the name of the new certifying accountant or the reasons for the change in this filing?
No, this filing only states that there has been a change in the certifying accountant but does not disclose the name of the new firm or the specific reasons for the change.
What was the former name of Hepion Pharmaceuticals, Inc. and when did the name change occur?
The former name of Hepion Pharmaceuticals, Inc. was ContraVir Pharmaceuticals, Inc., and the date of the name change was 20130806 (August 6, 2013), as stated in the 'FORMER COMPANY' section.
Filing Stats: 1,049 words · 4 min read · ~3 pages · Grade level 17.1 · Accepted 2024-01-03 16:30:24
Filing Documents
- tm241750d1_8k.htm (8-K) — 30KB
- tm241750d1_ex16-1.htm (EX-16.1) — 2KB
- tm241750d1_ex16-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-000860.txt ( ) — 208KB
- hepa-20231227.xsd (EX-101.SCH) — 3KB
- hepa-20231227_lab.xml (EX-101.LAB) — 33KB
- hepa-20231227_pre.xml (EX-101.PRE) — 22KB
- tm241750d1_8k_htm.xml (XML) — 3KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant. On December 27, 2023, the audit committee of the Board of Directors of Hepion Pharmaceuticals, Inc. (the "Company") approved the dismissal of BDO USA, P.C. ("BDO") as the Company's independent registered public accounting firm and approved the engagement of Grassi Advisors ("Grassi") as the Company's independent registered public accounting firm to audit the Company's consolidated financial statements for the year ended December 31, 2023. Accordingly, on January 1, 2024, BDO was informed that it would be dismissed as the Company's independent registered public accounting firm, effective immediately. The report of BDO on the Company's financial statements as of December 31, 2022 and 2021, and the related statements of operations, changes in stockholders' deficit and cash flows for the years ended December 31, 2021 and 2022 did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles, except that such report contained an explanatory paragraph which noted that there was substantial doubt as to the Company's ability to continue as a going concern because the Company has suffered recurring losses from operations and has an accumulated deficit . During the fiscal years ended December 31, 2022 and 2021, and the subsequent interim period through December 27, 2023, there have been no "reportable events" (as defined in Item 304(a)(1)(v) of Regulation S-K), except for the material weaknesses in the Company's internal control over financial reporting described in Part II, Item 9A, "Controls and Procedures," in the Company's annual reports on Form 10-K for the years ended December 31, 2022 and 2021, filed with the Securities and Exchange Commission (the "SEC") on April 10, 2023 and in Part I, Item 4, "Controls and Procedures," in the Company's quarterly reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and
01
Item 9.01 (d) Exhibits
Financial Statements and Exhibits
Financial Statements and Exhibits 16.1 Letter from BDO USA, P.C. to the Securities and Exchange Commission dated January 2, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -3- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 3, 2024 HEPION PHARMACEUTICALS, INC. By: /s/ John Cavan John Cavan Interim Chief Executive Officer -4-